Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome

Darlene Gabeau-Lacet, David Engler, Sumeet Gupta, George A. Scangas, Rebecca Betensky, Fred G. Barker, Jay S. Loeffler, David N. Louis, Gayatry Mohapatra

Research output: Contribution to journalArticle

Abstract

Atypical meningiomas exhibit heterogeneous clinical outcomes. It is unclear which atypical meningiomas require aggressive multimodality treatment with surgery and radiation therapy versus surgery alone to prevent recurrence. Detailed molecular-genetic characterization of these neoplasms is necessary to understand their pathogenesis and identify clinically relevant genetic markers. Oligonucleotide array comparative genomic hybridization was used to identify frequent genetic alterations in 47 primary atypical meningiomas resected at Massachusetts General Hospital between August 1987 and September 2006. Eighty-five percent of samples exhibited loss of 22q, including the neurofibromatosis type 2 gene. The second most frequent regions of loss were confined to the short arm of chromosome 1, particularly 1p33-p36.2 (70%) and 1p13.2 (64%). Other frequent regions of loss, detected in more than 50% of samples, included 14q, 10q, 8q, 7p, 21q, 19, 9q34, and 4p16. Frequent regions of gain were detected along 1q (59%), 17q (44%), 9q34 (30%), and 7q36 (26%). Univariate marker-by-marker analysis of all frequently identified copy number alterations showed potential correlation between gain of 1q and shorter progression-free survival. Given the heterogeneous treatment outcomes of atypical meningioma, investigation of large-scale and focal genomic alterations in multi-institutional efforts may help clarify molecular-genetic signatures of clinical use.

Original languageEnglish (US)
Pages (from-to)1155-1165
Number of pages11
JournalJournal of Neuropathology and Experimental Neurology
Volume68
Issue number10
DOIs
StatePublished - Oct 1 2009

Fingerprint

Meningioma
Molecular Biology
Neurofibromatosis 2 Genes
Neurofibromatosis 2
Comparative Genomic Hybridization
Chromosomes, Human, Pair 1
Oligonucleotide Array Sequence Analysis
Genetic Markers
General Hospitals
Disease-Free Survival
Radiotherapy
Recurrence
Neoplasms
Therapeutics

Keywords

  • Array comparative genomic hybridization
  • Atypical meningioma.

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome. / Gabeau-Lacet, Darlene; Engler, David; Gupta, Sumeet; Scangas, George A.; Betensky, Rebecca; Barker, Fred G.; Loeffler, Jay S.; Louis, David N.; Mohapatra, Gayatry.

In: Journal of Neuropathology and Experimental Neurology, Vol. 68, No. 10, 01.10.2009, p. 1155-1165.

Research output: Contribution to journalArticle

Gabeau-Lacet, D, Engler, D, Gupta, S, Scangas, GA, Betensky, R, Barker, FG, Loeffler, JS, Louis, DN & Mohapatra, G 2009, 'Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome', Journal of Neuropathology and Experimental Neurology, vol. 68, no. 10, pp. 1155-1165. https://doi.org/10.1097/NEN.0b013e3181ba3952
Gabeau-Lacet, Darlene ; Engler, David ; Gupta, Sumeet ; Scangas, George A. ; Betensky, Rebecca ; Barker, Fred G. ; Loeffler, Jay S. ; Louis, David N. ; Mohapatra, Gayatry. / Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome. In: Journal of Neuropathology and Experimental Neurology. 2009 ; Vol. 68, No. 10. pp. 1155-1165.
@article{c95109b0feb642569d988c4f1a02f653,
title = "Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome",
abstract = "Atypical meningiomas exhibit heterogeneous clinical outcomes. It is unclear which atypical meningiomas require aggressive multimodality treatment with surgery and radiation therapy versus surgery alone to prevent recurrence. Detailed molecular-genetic characterization of these neoplasms is necessary to understand their pathogenesis and identify clinically relevant genetic markers. Oligonucleotide array comparative genomic hybridization was used to identify frequent genetic alterations in 47 primary atypical meningiomas resected at Massachusetts General Hospital between August 1987 and September 2006. Eighty-five percent of samples exhibited loss of 22q, including the neurofibromatosis type 2 gene. The second most frequent regions of loss were confined to the short arm of chromosome 1, particularly 1p33-p36.2 (70{\%}) and 1p13.2 (64{\%}). Other frequent regions of loss, detected in more than 50{\%} of samples, included 14q, 10q, 8q, 7p, 21q, 19, 9q34, and 4p16. Frequent regions of gain were detected along 1q (59{\%}), 17q (44{\%}), 9q34 (30{\%}), and 7q36 (26{\%}). Univariate marker-by-marker analysis of all frequently identified copy number alterations showed potential correlation between gain of 1q and shorter progression-free survival. Given the heterogeneous treatment outcomes of atypical meningioma, investigation of large-scale and focal genomic alterations in multi-institutional efforts may help clarify molecular-genetic signatures of clinical use.",
keywords = "Array comparative genomic hybridization, Atypical meningioma.",
author = "Darlene Gabeau-Lacet and David Engler and Sumeet Gupta and Scangas, {George A.} and Rebecca Betensky and Barker, {Fred G.} and Loeffler, {Jay S.} and Louis, {David N.} and Gayatry Mohapatra",
year = "2009",
month = "10",
day = "1",
doi = "10.1097/NEN.0b013e3181ba3952",
language = "English (US)",
volume = "68",
pages = "1155--1165",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome

AU - Gabeau-Lacet, Darlene

AU - Engler, David

AU - Gupta, Sumeet

AU - Scangas, George A.

AU - Betensky, Rebecca

AU - Barker, Fred G.

AU - Loeffler, Jay S.

AU - Louis, David N.

AU - Mohapatra, Gayatry

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Atypical meningiomas exhibit heterogeneous clinical outcomes. It is unclear which atypical meningiomas require aggressive multimodality treatment with surgery and radiation therapy versus surgery alone to prevent recurrence. Detailed molecular-genetic characterization of these neoplasms is necessary to understand their pathogenesis and identify clinically relevant genetic markers. Oligonucleotide array comparative genomic hybridization was used to identify frequent genetic alterations in 47 primary atypical meningiomas resected at Massachusetts General Hospital between August 1987 and September 2006. Eighty-five percent of samples exhibited loss of 22q, including the neurofibromatosis type 2 gene. The second most frequent regions of loss were confined to the short arm of chromosome 1, particularly 1p33-p36.2 (70%) and 1p13.2 (64%). Other frequent regions of loss, detected in more than 50% of samples, included 14q, 10q, 8q, 7p, 21q, 19, 9q34, and 4p16. Frequent regions of gain were detected along 1q (59%), 17q (44%), 9q34 (30%), and 7q36 (26%). Univariate marker-by-marker analysis of all frequently identified copy number alterations showed potential correlation between gain of 1q and shorter progression-free survival. Given the heterogeneous treatment outcomes of atypical meningioma, investigation of large-scale and focal genomic alterations in multi-institutional efforts may help clarify molecular-genetic signatures of clinical use.

AB - Atypical meningiomas exhibit heterogeneous clinical outcomes. It is unclear which atypical meningiomas require aggressive multimodality treatment with surgery and radiation therapy versus surgery alone to prevent recurrence. Detailed molecular-genetic characterization of these neoplasms is necessary to understand their pathogenesis and identify clinically relevant genetic markers. Oligonucleotide array comparative genomic hybridization was used to identify frequent genetic alterations in 47 primary atypical meningiomas resected at Massachusetts General Hospital between August 1987 and September 2006. Eighty-five percent of samples exhibited loss of 22q, including the neurofibromatosis type 2 gene. The second most frequent regions of loss were confined to the short arm of chromosome 1, particularly 1p33-p36.2 (70%) and 1p13.2 (64%). Other frequent regions of loss, detected in more than 50% of samples, included 14q, 10q, 8q, 7p, 21q, 19, 9q34, and 4p16. Frequent regions of gain were detected along 1q (59%), 17q (44%), 9q34 (30%), and 7q36 (26%). Univariate marker-by-marker analysis of all frequently identified copy number alterations showed potential correlation between gain of 1q and shorter progression-free survival. Given the heterogeneous treatment outcomes of atypical meningioma, investigation of large-scale and focal genomic alterations in multi-institutional efforts may help clarify molecular-genetic signatures of clinical use.

KW - Array comparative genomic hybridization

KW - Atypical meningioma.

UR - http://www.scopus.com/inward/record.url?scp=70349748597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349748597&partnerID=8YFLogxK

U2 - 10.1097/NEN.0b013e3181ba3952

DO - 10.1097/NEN.0b013e3181ba3952

M3 - Article

VL - 68

SP - 1155

EP - 1165

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 10

ER -